Evidence map›Paper›PMID 34650125›Full record

ArticleScientific reports2021

Pan-cancer analysis of the prognostic and immunological role of PSMB8.

Danxiang Chen, Cong Jin, Xubin Dong, Jialiang Wen, Erjie Xia, Qingxuan Wang, Ouchen Wang

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2022
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Danxiang Chen *Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China.
Cong Jin *Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China.
Xubin Dong *Department of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China.
Jialiang WenDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China.
Erjie XiaDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China.
Qingxuan WangDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China. wangqingxuan1991@163.com.
Ouchen WangDepartment of Breast Surgery, The First Affiliated Hospital of Wenzhou Medical University, Nan Bai Xiang Street, Wenzhou, 325006, Zhejiang, China. woc@wmu.edu.cn.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently some evidence has demonstrated the significance of PSMB8 in various malignancies. Nevertheless, PSMB8 (proteasome subunit beta 8), more familiar in the field of immunology contributing to the process of antigen presentation, is indeterminate in the role as a survival predictor of human pan-cancer. Besides, how PSMB8 interacts with immune cell infiltration in the tumor microenvironment requires further research. We then penetrated into the analysis of the PSMB8 expression profile among 33 types of cancer in the TCGA database. The results show that overexpression of PSMB8 was associated with poor clinical outcomes in overall survival (Sartorius et al. in Oncogene 35(22):2881-2892, 2016), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) in most cancer varieties. In addition, there existed distinctly positive correlations between PSMB8 and immunity, reflected straightforwardly in the form of immune scores, tumor-infiltrating immune cells (TIICs) abundance, microsatellite instability, tumor mutation burden, and neoantigen level. Notably, specific markers of dendrite cells exhibited the tightest association with PSMB8 expression in terms of tumor-related immune infiltration patterns. Moreover, gene enrichment analysis showed that elevated PSMB8 expression was related to multiple immune-related pathways. We finally validated the PSMB8 expression in our local breast samples via quantitative PCR assays and concluded that PSMB8 appeared to perform well in predicting the survival outcome of BRCA patients. These findings elucidate the pivotal role of the antigen presentation-related gene PSMB8, which could potentially serve as a robust biomarker for prognosis determination in multiple cancers.

Indexed as

Biomarkers, TumorDatabases, GeneticGene Expression Regulation, NeoplasticHumansMicrosatellite InstabilityNeoplasmsOncogenesPrognosisProteasome Endopeptidase ComplexSurvival AnalysisTumor MicroenvironmentBiomarkers, TumorProteasome Endopeptidase Complex

Identifiers

PMID34650125
PMCPMC8516870
OpenAlexW3206624041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.